Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 422

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation

Open access
Gilan, Omer, Rioja, Inmaculada, Knezevic, Kathy, Bell, Matthew J., Yeung, Miriam M., Harker, Nicola R., Lam, Enid Y. N., Chung, Chun-wa, Bamborough, Paul, Petretich, Massimo, Urh, Marjeta, Atkinson, Stephen J., Bassil, Anna K., Roberts, Emma J., Vassiliadis, Dane, Burr, Marian L., Preston, Alex G. S., Wellaway, Christopher, Werner, Thilo, Gray, James R., Michon, Anne-Marie, Gobbetti, Thomas, Kumar, Vinod, Soden, Peter E., Haynes, Andrea, Vappiani, Johanna, Tough, David F., Taylor, Simon, Dawson, Sarah-Jane, Bantscheff, Marcus, Lindon, Matthew, Drewes, Gerard, Demont, Emmanuel H., Daniels, Danette L., Grandi, Paola, Prinjha, Rab K., Dawson, Mark A.·2020·Science

Abstract

Bromodomain inhibitors revisited: Bromodomain and extraterminal domain (BET) proteins contribute to the pathogenesis of cancer and immune diseases through their effects on transcriptional regulation. BET proteins contain two nearly identical bromodomains, BD1 and BD2, structural modules that have attracted great interest as targets for drug development. First-generation drugs that inhibited both BD1 and BD2 showed promising therapeutic activity in preclinical models but proved to be less efficacious in clinical trials. Gilan et al. took a different approach and designed drugs that selectively inhibited BD1 or BD2 (see the Perspective by Filippakopoulos and Knapp). They found that BD1 and BD2 inhibitors altered gene expression in different ways and that BD2 inhibitors had greater therapeutic activity than BD1 inhibitors in preclinical models of inflammation and autoimmune disease. Science , this issue p. 387 ; see also p. 367

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1126/science.aaz8455

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 43 references

Cited by

See all 422

Metadata

Authors
Gilan, O., Rioja, I., Knezevic, K., Bell, M. J., Yeung, M. M., Harker, N. R., Lam, E. Y. N., Chung, C.-W., Bamborough, P., Petretich, M., Urh, M., Atkinson, S. J., Bassil, A. K., Roberts, E. J., Vassiliadis, D., Burr, M. L., Preston, A. G. S., Wellaway, C., Werner, T., Gray, J. R., Michon, A.-M., Gobbetti, T., Kumar, V., Soden, P. E., Haynes, A., Vappiani, J., Tough, D. F., Taylor, S., Dawson, S.-J., Bantscheff, M., Lindon, M., Drewes, G., Demont, E. H., Daniels, D. L., Grandi, P., Prinjha, R. K., & Dawson, M. A.
Venue
Science
Published
2020-04-24
Volume
368
Issue
6489
Pages
387-394
ISSN
  • 0036-8075 (ISSN-L)
  • 1095-9203
OpenAlex
W3011089475
Cited by
422
References
43
FWCI
18.39
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation. https://app.cochat.ai/papers/10.1126/science.aaz8455
The paper
Gilan, O., Rioja, I., Knezevic, K., Bell, M. J., Yeung, M. M., Harker, N. R., Lam, E. Y. N., Chung, C.-W., Bamborough, P., Petretich, M., Urh, M., Atkinson, S. J., Bassil, A. K., Roberts, E. J., Vassiliadis, D., Burr, M. L., Preston, A. G. S., Wellaway, C., Werner, T., . . . Dawson, M. A. (2020). Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation. Science. https://doi.org/10.1126/science.aaz8455

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.